samedan logo
home > pmps > winter 2020 > an exercise in quality risk management
Pharmaceutical Manufacturing and Packing Sourcer

An Exercise in Quality Risk Management

The terms extractable and leachable (E&L) have almost become a grammatical contraction for some, but this is a mistake. The terms are distinct and must not be blended into one. When fully understood, both are essential and complementary with different roles in quality risk management.

The Difference Between Extractables and Leachables

‘Extractable’, and its accompanying term ‘extractable study’, was coined to describe a wide number of experimental studies conducted on materials used in pharmaceutical packaging, devices, and manufacture to generate knowledge and understanding of the impurities found in these materials under study. Which system one chooses to study is directed by need and experience. This topic area of E&L was created from a realisation that the quality of the packaging system used in some dose forms was a potential contamination source for drug products, and thus a risk to patient safety.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the author

Jason Creasey recently set up Maven E&L to provide independent consultant advice in the area of E&L. He has worked in this topic area since the mid-1990s. Prior to setup, Jason was the Director of a team of analytical chemists providing GSK’s global R&D support for E&L activities. This included: biopharmaceutical and small molecules such as inhalation, parenteral, and cell and gene therapy use. He has been a member of several external groups concerned with best practice guides for E&L issues and continues as a scientific advisor to Extractable and Leachable Safety Information Exchange.
Print this page
Send to a friend
Privacy statement
News and Press Releases

First own Gerresheimer Autoinjector - Gerresheimer and Midas Pharma announce strategic partnership

– Gerresheimer’s first own IP autoinjector suitable for both small and large molecules enhances broad portfolio of solutions, medical devices and pharmaceutical primary packaging – First joint project of Gerresheimer and Midas Pharma: Development and marketing of new autoinjector – One-stop-shop for biotech and pharma customers Duesseldorf, November 08, 2021 – Gerresheimer acquired the IP of a new generation cartridge based autoinjector from Midas Pharma. This is the start of a strategic partnership. The joint project comprises the development and marketing of the new generation autoinjector.
More info >>

White Papers

The Use of Stainless Steel Equipment Within Laboratories and Clean Rooms

Teknomek Ltd

Teknomek explains why stainless steel is the material of choice for laboratories and hygienic manufacturing.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement